Efficacy of three COVID-19 vaccine doses in lung transplant recipients : a multicentre cohort study
Copyright ©The authors 2023..
QUESTION ADDRESSED BY THE STUDY: Do three coronavirus disease 2019 (COVID-19) vaccine doses induce a serological response in lung transplant recipients?.
METHODS: We retrospectively included 1071 adults (551 (52%) males) at nine transplant centres in France. Each had received three COVID-19 vaccine doses in 2021, after lung transplantation. An anti-spike protein IgG response, defined as a titre >264 BAU·mL-1 after the third dose (median (interquartile range (IQR)) 3.0 (1.7-4.1) months), was the primary outcome and adverse events were the secondary outcomes. Median (IQR) age at the first vaccine dose was 54 (40-63) years and median (IQR) time from transplantation to the first dose was 64 (30-110) months.
RESULTS: Median (IQR) follow-up after the first dose was 8.3 (6.7-9.3) months. A vaccine response developed in 173 (16%) patients. Factors independently associated with a response were younger age at vaccination, longer time from transplantation to vaccination and absence of corticosteroid or mycophenolate therapy. After vaccination, 51 (5%) patients (47 non-responders (47/898 (5%)) and four (4/173 (2%)) responders) experienced COVID-19, at a median (IQR) of 6.6 (5.1-7.3) months after the third dose. No responders had severe COVID-19 compared with 15 non-responders, including six who died of the disease.
CONCLUSIONS: Few lung transplant recipients achieved a serological response to three COVID-19 vaccine doses, indicating a need for other protective measures. Older age and use of mycophenolate or corticosteroids were associated with absence of a response. The low incidence of COVID-19 might reflect vaccine protection via cellular immunity and/or good adherence to shielding measures.
| Errataetall: |
CommentIn: Eur Respir J. 2023 Jan 19;61(1):. - PMID 36657779 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
The European respiratory journal - 61(2023), 1 vom: 20. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dauriat, Gaëlle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.01.2023 Date Revised 23.03.2023 published: Electronic-Print CommentIn: Eur Respir J. 2023 Jan 19;61(1):. - PMID 36657779 Citation Status MEDLINE |
|---|
| doi: |
10.1183/13993003.00502-2022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347805264 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347805264 | ||
| 003 | DE-627 | ||
| 005 | 20231226034716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/13993003.00502-2022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347805264 | ||
| 035 | |a (NLM)36265877 | ||
| 035 | |a (PII)2200502 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dauriat, Gaëlle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of three COVID-19 vaccine doses in lung transplant recipients |b a multicentre cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2023 | ||
| 500 | |a Date Revised 23.03.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a CommentIn: Eur Respir J. 2023 Jan 19;61(1):. - PMID 36657779 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright ©The authors 2023. | ||
| 520 | |a QUESTION ADDRESSED BY THE STUDY: Do three coronavirus disease 2019 (COVID-19) vaccine doses induce a serological response in lung transplant recipients? | ||
| 520 | |a METHODS: We retrospectively included 1071 adults (551 (52%) males) at nine transplant centres in France. Each had received three COVID-19 vaccine doses in 2021, after lung transplantation. An anti-spike protein IgG response, defined as a titre >264 BAU·mL-1 after the third dose (median (interquartile range (IQR)) 3.0 (1.7-4.1) months), was the primary outcome and adverse events were the secondary outcomes. Median (IQR) age at the first vaccine dose was 54 (40-63) years and median (IQR) time from transplantation to the first dose was 64 (30-110) months | ||
| 520 | |a RESULTS: Median (IQR) follow-up after the first dose was 8.3 (6.7-9.3) months. A vaccine response developed in 173 (16%) patients. Factors independently associated with a response were younger age at vaccination, longer time from transplantation to vaccination and absence of corticosteroid or mycophenolate therapy. After vaccination, 51 (5%) patients (47 non-responders (47/898 (5%)) and four (4/173 (2%)) responders) experienced COVID-19, at a median (IQR) of 6.6 (5.1-7.3) months after the third dose. No responders had severe COVID-19 compared with 15 non-responders, including six who died of the disease | ||
| 520 | |a CONCLUSIONS: Few lung transplant recipients achieved a serological response to three COVID-19 vaccine doses, indicating a need for other protective measures. Older age and use of mycophenolate or corticosteroids were associated with absence of a response. The low incidence of COVID-19 might reflect vaccine protection via cellular immunity and/or good adherence to shielding measures | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Beaumont, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Luong Nguyen, Liem Binh |e verfasserin |4 aut | |
| 700 | 1 | |a Renaud Picard, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Penhouet, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Coiffard, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Salpin, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Demant, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Saint Raymond, Christel |e verfasserin |4 aut | |
| 700 | 1 | |a Carlier, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Messika, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Reynaud Gaubert, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Danner, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Gallais, Floriane |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Le Pavec, Jérôme |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d 1989 |g 61(2023), 1 vom: 20. Jan. |w (DE-627)NLM012664782 |x 0903-1936 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:1 |g day:20 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/13993003.00502-2022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 1 |b 20 |c 01 | ||